



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/470008/2023

European Medicines Agency decision P/0444/2023

of 27 October 2023

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ruzotolimod, (EMA-003363-PIP01-22) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0444/2023

of 27 October 2023

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for ruzotolimod, (EMA-003363-PIP01-22) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the application submitted by Roche Registration GmbH on 18 November 2022 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 8 September 2023, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

A paediatric investigation plan for ruzotolimod, age-appropriate oral solid dosage form, tablets, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for ruzotolimod, age-appropriate oral solid dosage form, tablets, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

A waiver for ruzotolimod, age-appropriate oral solid dosage form, tablets, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 4

This decision is addressed to Roche Registration GmbH, Emil-Barell-Straße 1, Grenzach, 79639 - Grenzach-Wyhlen, Germany.



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/285618/2023
Amsterdam, 8 September 2023

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-003363-PIP01-22

Scope of the application

Active substance(s):

Ruzotolimod

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of chronic hepatitis B

Pharmaceutical form(s):

Age-appropriate oral solid dosage form

Tablets

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Roche Registration GmbH

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Roche Registration GmbH submitted for agreement to the European Medicines Agency on 18 November 2022 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.

The procedure started on 3 January 2023.

Supplementary information was provided by the applicant on 17 May 2023. The applicant proposed modifications to the paediatric investigation plan.



Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation;
- to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with

Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of chronic hepatitis B

The waiver applies to:

- the paediatric population from birth to less than 2 years of age;
- Age-appropriate oral solid dosage form; oral use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition:

Treatment of chronic hepatitis B

2.1.1. Indication(s) targeted by the PIP

Treatment of chronic hepatitis B

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 years of age to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Age-appropriate oral solid dosage form

2.1.4. Measures

| Area | Description |
|----------------------------------|--|
| Quality-related studies | Study 1 (Age-appropriate oral solid dosage form) Development of age-appropriate oral solid dosage form for use in children from 2 years to less than 18 years of age. |
| Non-clinical studies | Not applicable. |
| Clinical studies | Study 2 Randomized, parallel group, open label, two-part study of safety and efficacy of a finite-duration combination of ruzotolimod and xalnesiran compared with standard of care in children with chronic hepatitis B from 2 years of age to less than 18 years of age. |
| Modelling and simulation studies | Study 3 Population PK (/PD) model; dose-finding. |

| | |
|--------------------|-----------------|
| Other studies | Not applicable. |
| Extrapolation plan | Not applicable. |

3. Follow-up, completion and deferral of PIP

| | |
|---|----------------|
| Concerns on potential long term safety/efficacy issues in relation to paediatric use: | No |
| Date of completion of the paediatric investigation plan: | By August 2034 |
| Deferral for one or more measures contained in the paediatric investigation plan: | Yes |

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community.